Investigational drug · Phase 3
TSC-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for AML, MDS.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "TSC-101"
First trial start
2026
Jun 18, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TSC-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- AML
- MDS
Largest trials
Live from ClinicalTrials.gov: studies naming "TSC-101" as an intervention, largest first.
- A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)Active, not recruiting
TScan Therapeutics, Inc.Industry
NCT05473910 · 310 participants (planned) · Start Nov 1, 2022 · Primary completion Jun 1, 2026
Drug: SOC + TSC-101; SOC + TSC-100 · For: AML; MDS
Sites: Duarte, California; Aurora, Colorado; Denver, Colorado · 21 sites in all
- A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell TransplantationPivotal-lookingActive, not recruiting
TScan Therapeutics, Inc.Industry
NCT07702578 · 310 participants (planned) · Start Jun 18, 2026 · Primary completion Jun 2029
Drug: TSC-101 · For: AML; MDS
Sites: Gilbert, Arizona; Scottsdale, Arizona; Duarte, California · 26 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for AML
- JAB-8263Phase 22 trials
Jacobio Pharmaceuticals Co., Ltd. · Rheumatoid Arthritis (RA), NSCLC, SCLC
- CFI-400945Phase 21 trial
Treadwell Therapeutics, Inc · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.